PetMed Express, Inc. (NASDAQ:PETS) Might Not Be As Mispriced As It Looks After Plunging 33%
PetMed Express, Inc. (NASDAQ:PETS) Might Not Be As Mispriced As It Looks After Plunging 33%
Unfortunately for some shareholders, the PetMed Express, Inc. (NASDAQ:PETS) share price has dived 33% in the last thirty days, prolonging recent pain. The recent drop completes a disastrous twelve months for shareholders, who are sitting on a 69% loss during that time.
不幸的是,對於一些股東來說, PetMed Express, In 納斯達克股票代碼:PETS)的股價在過去三十天中下跌了33%,延續了最近的痛苦。對於股東來說,最近的下跌結束了災難性的十二個月,在此期間,他們的虧損爲69%。
In spite of the heavy fall in price, you could still be forgiven for feeling indifferent about PetMed Express' P/S ratio of 0.5x, since the median price-to-sales (or "P/S") ratio for the Specialty Retail industry in the United States is also close to 0.3x. However, investors might be overlooking a clear opportunity or potential setback if there is no rational basis for the P/S.
儘管價格大幅下跌,但你對PetMed Express的0.5倍市盈率漠不關心仍然是可以原諒的,因爲美國專業零售行業的中位數市盈率(或 “市盈率”)也接近0.3倍。但是,如果市盈率沒有合理的基礎,投資者可能會忽視明顯的機會或潛在的挫折。
View our latest analysis for PetMed Express
查看我們對PetMed Express的最新分析
What Does PetMed Express' Recent Performance Look Like?
PetMed Express 最近的表現是什麼樣子?
PetMed Express' revenue growth of late has been pretty similar to most other companies. Perhaps the market is expecting future revenue performance to show no drastic signs of changing, justifying the P/S being at current levels. Those who are bullish on PetMed Express will be hoping that revenue performance can pick up, so that they can pick up the stock at a slightly lower valuation.
PetMed Express最近的收入增長與大多數其他公司非常相似。也許市場預計未來的收入表現不會顯示出劇烈變化的跡象,這證明市盈率保持在當前水平是合理的。那些看好PetMed Express的人希望收入表現能夠回升,這樣他們就可以以略低的估值買入該股。
How Is PetMed Express' Revenue Growth Trending?
PetMed Express 的收入增長趨勢如何?
There's an inherent assumption that a company should be matching the industry for P/S ratios like PetMed Express' to be considered reasonable.
人們固有的假設是,一家公司應該與行業相提並論,這樣像PetMed Express這樣的市盈率才算合理。
If we review the last year of revenue growth, the company posted a worthy increase of 3.1%. Ultimately though, it couldn't turn around the poor performance of the prior period, with revenue shrinking 12% in total over the last three years. Accordingly, shareholders would have felt downbeat about the medium-term rates of revenue growth.
如果我們回顧一下去年的收入增長,該公司公佈了3.1%的可觀增長。但是,它最終無法扭轉前一時期的糟糕表現,在過去三年中,總收入下降了12%。因此,股東們會對中期收入增長率感到悲觀。
Shifting to the future, estimates from the two analysts covering the company suggest revenue should grow by 16% over the next year. Meanwhile, the rest of the industry is forecast to only expand by 6.6%, which is noticeably less attractive.
展望未來,報道該公司的兩位分析師的估計表明,明年收入將增長16%。同時,該行業的其他部門預計僅增長6.6%,這明顯降低了吸引力。
With this in consideration, we find it intriguing that PetMed Express' P/S is closely matching its industry peers. Apparently some shareholders are skeptical of the forecasts and have been accepting lower selling prices.
考慮到這一點,我們發現有趣的是,PetMed Express的市盈率與行業同行非常接近。顯然,一些股東對預測持懷疑態度,並一直在接受較低的銷售價格。
What Does PetMed Express' P/S Mean For Investors?
PetMed Express的市盈率對投資者意味着什麼?
PetMed Express' plummeting stock price has brought its P/S back to a similar region as the rest of the industry. Generally, our preference is to limit the use of the price-to-sales ratio to establishing what the market thinks about the overall health of a company.
PetMed Express的股價暴跌使其市盈率回到了與該行業其他公司相似的區域。通常,我們傾向於將價格與銷售比率的使用限制在確定市場對公司整體健康狀況的看法上。
We've established that PetMed Express currently trades on a lower than expected P/S since its forecasted revenue growth is higher than the wider industry. Perhaps uncertainty in the revenue forecasts are what's keeping the P/S ratio consistent with the rest of the industry. It appears some are indeed anticipating revenue instability, because these conditions should normally provide a boost to the share price.
我們已經確定,PetMed Express目前的市盈率低於預期,因爲其預測的收入增長高於整個行業。也許收入預測的不確定性是使市盈率與行業其他部門保持一致的原因。看來有些人確實在預測收入不穩定,因爲這些條件通常應該會提振股價。
It's always necessary to consider the ever-present spectre of investment risk. We've identified 1 warning sign with PetMed Express, and understanding should be part of your investment process.
始終需要考慮永遠存在的投資風險幽靈。我們已經確定了 1 個帶有 PetMed Express,理解應該是你投資過程的一部分。
If these risks are making you reconsider your opinion on PetMed Express, explore our interactive list of high quality stocks to get an idea of what else is out there.
如果這些 風險讓你重新考慮你對 PetMed Express 的看法,瀏覽我們的高品質股票互動清單,了解還有什麼。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
對這篇文章有反饋嗎?擔心內容嗎? 取得聯繫 直接和我們在一起。 或者,給編輯團隊 (at) simplywallst.com 發送電子郵件。
Simply Wall St 的這篇文章本質上是籠統的。 我們僅使用公正的方法根據歷史數據和分析師的預測提供評論,我們的文章無意作爲財務建議。 它不構成買入或賣出任何股票的建議,也沒有考慮您的目標或財務狀況。我們的目標是爲您提供由基本面數據驅動的長期重點分析。請注意,我們的分析可能不考慮最新的價格敏感公司公告或定性材料。簡而言之,華爾街在上述任何股票中都沒有頭寸。